Skip to main content

Table 2 Univariate Cox hazard proportional analyses for progression-free survival in the upfront ABI group

From: Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

Variables

Factor

P value

Hazard ratio

95% CI

Age

≥75 years

0.780

0.85

0.27-2.78

ECOG-PS

≥1

0.150

2.09

0.76-5.75

Initial PSA

≥100 ng/ml

0.230

2.60

0.54-12.5

Gleason score

≥9

0.438

0.67

0.24-1.85

Visceral metastasis

presence

0.380

0.51

0.11-2.29

EOD

0-4

0.375

1.29

0.74-2.24

ALP

≥322 IU/L

0.290

1.97

0.56-6.98

LDH

≥222 IU/L

0.019

3.70

1.24-11.0

Anemia

presence

0.002

5.58

1.90-16.4

  1. ABI abiraterone acetate, CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, PSA prostate specific antigen, EOD extent of disease, ALP alkaline phosphatase, LDH lactate dehydrogenase